Therapeutic advances have resulted in a growing population of childhood cancer survivors. Unfortunately, this success comes at a price. A substantial proportion of the survivors develop ...

The integration of targeted therapies into neuro-oncology is revolutionizing the management of primary CNS malignancies. Advances in sequencing technologies and the incorporation of molecular ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

Educational Video as an Alternative to Pretest In-Person Genetic Counseling in Candidates for Cancer Genetic Testing: A Randomized Controlled Noninferiority Trial Hepatocellular carcinoma (HCC) is the ...

Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group SLM demonstrated high sensitivity (99.4%) and accuracy (95.3%) in ...

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal ...

Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas Pancreatic ...

JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published three times a month, JCO is the foremost peer-reviewed journal focusing on clinical ...

Peer Navigation for HIV-Associated Kaposi Sarcoma in Kenya: The Power of the Survivor's Voice Latin America's cultural diversity, political instability, and socioeconomic inequality contribute to ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Erratum: Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis In the article that ...